Alnylam Pharmaceuticals, a leader in RNAi therapeutics, is a biopharmaceutical company developing novel therapeutics based on a breakthrough in biology known as RNA interference, or RNAi; a discovery that enables the creation of a broad new class of human therapeutics. Using RNAi, Alnylam has built a product engine to develop a deep pipeline of drug products to treat a wide array of important diseases. learn more
The central dogma of biology is that DNA makes RNA which in turn, makes protein. The abnormal production of proteins is the cause of most human disease. Today's drugs act by blocking the action of disease-causing proteins. RNAi creates the opportunity to silence the production of disease-causing proteins and therefore, represents a whole new approach for innovative medicines.
Alnylam is supported by strong financial resources and world class collaborators to build a pipeline of RNAi products.
Corporate Governance SEC Filings Media Kit 1Q'08 Financial Results, May 8 @ Bank of America, May 14 @ Rodman & Renshaw, May 19
